9 completed, 2 active not recruiting. 10 Phase 3, 1 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 10 | Completed 8, Active not recruiting 2 |
| Phase 4 | 1 | Completed 1 |
Follow RotaTeq™: new trials by email Literature Review of RotaTeq™ trials Research Report on RotaTeq™
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization | Phase 3 | Active not recruiting | Sanofi | 580 | 2025-02-27 | 2026-02-13 |
| Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age PCV21 vaccine, Prevnar 20 vaccine, M-M-R II vaccine - Pneumococcal Immunization | Phase 3 | Active not recruiting | Sanofi | 2360 | 2025-02-18 | 2026-04-13 |
| Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029) V114, Prevnar 13™, RotaTeq™ - Pneumococcal Infections, Pneumococcal Vaccines | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1720 | 2019-06-19 | 2023-07-28 |
| A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION) Prevnar 13™, V114, RotaTeq™ - Pneumococcal Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 900 | 2018-10-18 | 2023-01-17 |
| Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060) RotaTeq™ (V260), DTP-IPV - Rotavirus Disease | Phase 4 | Completed | Merck Sharp & Dohme LLC | 192 | 2013-09-19 | 2018-11-14 |
| A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006) V419, PENTACEL™, Prevnar 13™ - Bacterial Infections, Virus Diseases | Phase 3 | Completed | Merck Sharp & Dohme LLC | 2808 | 2011-05-10 | 2018-11-15 |
| Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005) V419, DAPTACEL™, PedvaxHIB™ - Bacterial Infections, Virus Diseases | Phase 3 | Completed | Merck Sharp & Dohme LLC | 1473 | 2011-04-19 | 2018-11-15 |
| Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED) Rotavirus Vaccine, Live, Oral, Pentavalent (V260, RotaTeq™), Comparator: Comparator: Placebo (unspecified) - Rotavirus, Gastroenteritis | Phase 3 | Completed | Merck Sharp & Dohme LLC | 762 | 2008-08-01 | 2017-04-13 |
| Developing World Study for RotaTeq™ (V260-015)(COMPLETED) RotaTeq™ - Rotavirus Vaccine, Live, Oral, Pentavalent, Comparator: Placebo - Vomiting, Diarrhea | Phase 3 | Completed | Merck Sharp & Dohme LLC | 7504 | 2007-03-01 | 2017-04-13 |
| Consistency Lots Vaccine Study (V260-009) rotavirus vaccine, live, oral, pentavalent, Placebo - Rotavirus Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 793 | 2003-05-01 | 2015-10-05 |
| Rotavirus Efficacy and Safety Trial (REST)(V260-006) Rotateq™, Comparator: Placebo - Rotavirus Infections | Phase 3 | Completed | Merck Sharp & Dohme LLC | 69274 | 2001-01-01 | 2015-10-05 |
Rotavirus Infections (3) · Bacterial Infections (2) · Diphtheria (2) · Haemophilus Infections (2) · Hepatitis B (2) · Pneumococcal Infections (2) · Poliomyelitis (2) · Tetanus (2) · Virus Diseases (2) · Whooping Cough (2) · Diarrhea (1) · Fever (1) · Gastroenteritis (1) · Vomiting (1)
Merck Sharp & Dohme LLC (9) · Sanofi (2)
United States (4) · Puerto Rico (3) · Thailand (3) · Turkey (Türkiye) (3) · Mexico (2) · Chile (1) · Honduras (1) · Philippines (1)
PMID 16394299, PMID 20540778, PMID 20692030, PMID 20692031, PMID 23732903, PMID 27755463, PMID 27846058, PMID 28140752, PMID 29564996, PMID 36522265, PMID 36621410, PMID 37846456
2018 (2)